Eli Lilly's (LLY) Fundamentals and Pipeline are Encouraging, Continue to Support Positive View - BMO Capital Markets

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. HTFL
7. ADYEN:NA
8. ADYYF
9. WDAY
10. DVLT

Go back to Eli Lilly's (LLY) Fundamentals and Pipeline are Encouraging, Continue to Support Positive View - BMO Capital Markets

Eli Lilly (LLY) PT Lowered to $305 at BMO Capital

February 4, 2022 6:55 AM EST

BMO Capital analyst Evan David Seigerman lowered the price target on Eli Lilly (NYSE: LLY) to $305.00 (from $310.00) while maintaining an Outperform rating.

The analyst commented, "Donanemab concerns overshadow a solid quarter and set up into 2022. Despite solid set of 4Q21 results and reiterated... More

Eli Lilly's (LLY) Earnings Outlook Continues to Look Favorable VS Peers, Reiterate Overweight - Cantor Fitzgerald

February 3, 2022 7:13 AM EST

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $335.00 price target on Eli Lilly (NYSE: LLY), following the company's Q4 earnings report.

The analyst quotes: "Post a 4Q21 sales (beat versus FactSet for Trulicity, Taltz, Jardiance and Verzenio, among other... More

Eli Lilly pushes back timeline for Alzheimer's drug application

February 3, 2022 6:35 AM EST

By Leroy Leo

(Reuters) - Eli Lilly and Co deferred its timeline to complete application for accelerated approval of its experimental Alzheimer's drug, saying it expects such an approval to make little difference with Medicare's limited coverage terms.

Shares of Eli Lilly fell 2.6% to $244.21 on Thursday, after the drugmaker said it would complete the application sometime later in 2022, pushing away from first quarter, its initial timeline.

The U.S. Centers for Medicaid and Medicare Services... More

Eli Lilly & Co. (LLY) Tops Q4 EPS by 34c, Revenue Beats, Offers Guidance

February 3, 2022 6:26 AM EST

Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $2.49, $0.34 better than the analyst estimate of $2.15. Revenue for the quarter came in at $8 billion versus the consensus estimate of $6.74 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2022 EPS of $8.50-$8.65, versus the... More